CAJ | 학술논문

目的：观察奥美拉唑联合伊托必利治疗反流性食管炎的疗效及对生活质量的影响。方法选取2012年3月～2013年3月116例食管反流病患者，随机分为两组，对照组58例给予奥美拉唑治疗，观察组58例在对照组基础上给予伊托必利治疗，比较观察两组的症状变化、临床疗效、生活质量以及不良反应情况。结果两组治疗后烧心、反酸和胸骨后疼痛评分为（2.32±0.24）、（1.98±0.32）、（2.36±0.26）和（1.61±0.17）、（1.16±0.25）、（1.69±0.19），与治疗前比较发生明显下降（t=4.012，3.984，4.223，6.231，5.982，7.014，P＜0.05）；观察组治疗后各评分明显低于对照组（t=3.992，4.013，4.114，P＜0.05）。观察组的痊愈率和总有效率分别为32.8%和91.4%，明显高于对照组的13.8%和72.4%（x2=5.841，7.036，P＜0.05）。观察组治疗后1个月、3个月和6个月生活质量评分均明显高于对照组（t=4.235，5.132，4.331，P＜0.05）。两组不良反应比较无统计学意义（x2=0.537，0.648，0.559，P＞0.05）。结论奥美拉唑联合伊托必利治疗反流性食管炎能够缓解临床症状，提高治疗效果，改善生活质量，并且不良反应少，值得临床推广应用。
목적：관찰오미랍서연합이탁필리치료반류성식관염적료효급대생활질량적영향。방법선취2012년3월～2013년3월116례식관반류병환자，수궤분위량조，대조조58례급여오미랍서치료，관찰조58례재대조조기출상급여이탁필리치료，비교관찰량조적증상변화、림상료효、생활질량이급불량반응정황。결과량조치료후소심、반산화흉골후동통평분위（2.32±0.24）、（1.98±0.32）、（2.36±0.26）화（1.61±0.17）、（1.16±0.25）、（1.69±0.19），여치료전비교발생명현하강（t=4.012，3.984，4.223，6.231，5.982，7.014，P＜0.05）；관찰조치료후각평분명현저우대조조（t=3.992，4.013，4.114，P＜0.05）。관찰조적전유솔화총유효솔분별위32.8%화91.4%，명현고우대조조적13.8%화72.4%（x2=5.841，7.036，P＜0.05）。관찰조치료후1개월、3개월화6개월생활질량평분균명현고우대조조（t=4.235，5.132，4.331，P＜0.05）。량조불량반응비교무통계학의의（x2=0.537，0.648，0.559，P＞0.05）。결론오미랍서연합이탁필리치료반류성식관염능구완해림상증상，제고치료효과，개선생활질량，병차불량반응소，치득림상추엄응용。
Objective To observe the curative effect of omeprazole combined with itopride in the treatment of reflux esophagitis and its effect on life quality. Methods 116 patients with reflux esophagitis from March 2012 to March 2013 were randomly allocated to two groups.58 patients in the control group were given omeprazole,and another 58 patients in the control group were further given Itopride.Changes of symptoms, clinical effect,life quality and adverse events between the two group were observed and compared. Results Scores of heartburn,acid regurgitation and retrosternal pain in the two groups after the treatment were(2.32±0.24),(1.98±0.32),(2.36±0.26)and(1.61±0.17), (1.16±0.25),(1.69±0.19)respectively,significantly lower than those before the treatment(t=4.012,3.984,4.223,6.23 1,5.982,7.014,P<0.05);scores in the observation group after the treatment were significantly lower than those in the control group(t=3.992, 4.013,4.114,P < 0.05).Recovery rate and total effective rate in the observation group were 32.8%and 91.4%, significantly higher than those of 13.8%and 72.4%in the control group(x2=5.841,7.036,P<0.05). Life quality in 1 month,3 months and 6 months after the treatment in the observation group were all significantly higher than those in the control group(t=4.235,5.132,4.331,P<0.05).Difference of adverse events between the two groups were not statistically significant(x2=0.537,0.648,0.559,P>0.05). Conclusion Omeprazole combined with itopride in the treatment of reflux esophagitis helps alleviate clinical symptoms,improve curative effect,enhance life quality and reduce adverse events,which is worthy of clinical promotion and application.